Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre

Acquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3...
March 26, 2019 19:33 ET | Source: Novartis Pharma AG

Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease

Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients...
March 22, 2019 02:00 ET | Source: Novartis Pharma AG

Novartis plans for Alcon spin-off on April 9, 2019

Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange...
March 18, 2019 02:15 ET | Source: Novartis Pharma AG

Alcon Announces Acquisition of PowerVision, Inc.

Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire spectacle...
March 14, 2019 12:30 ET | Source: Novartis Pharma AG

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy

Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019...
March 14, 2019 05:00 ET | Source: Novartis Pharma AG

Novartis führt in der Schweiz bezahlte Elternauszeit von 18 Wochen ein

Basierend auf der neuen, globalen Richtlinie für Elternauszeit, die eine Absenz von mindestens 14 Wochen vorsieht, führt Novartis in der Schweiz ab 1. Juli 2019 eine bezahlte Elternauszeit von 18...
March 14, 2019 05:00 ET | Source: Novartis Pharma AG

Novartis instaure un congé parental rémunéré de 18 semaines en Suisse

Novartis instaurera un congé parental rémunéré de 18 semaines en Suisse à compter du 1er juillet 2019 en ligne avec sa nouvelle directive mondiale sur le congé parental, qui prévoit un congé d'au...
March 14, 2019 02:15 ET | Source: Novartis Pharma AG

Novartis announces change in Sandoz leadership

Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced...
March 10, 2019 19:35 ET | Source: Novartis Pharma AG

Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW

Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and...
March 05, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*

New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16...